[{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"MaaT Pharma \/ SymBiosis","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ SymBiosis"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"enema","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Skyepharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Skyepharma","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Skyepharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"MaaT033","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule, Delayed Release","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MaaT013","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MaaT Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"MaaT033","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MaaT Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by MaaT Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
